Tipalti expands offering to European businesses with the launch of a dedicated European product and new EMI licence
Tipalti, the leading finance automation platform, today announces the launch of a fully localised solution for the European market, along with a recently granted Electronic Money Institution (EMI) licence from De Nederlandsche Bank (DNB).
Manual finance processes continue to swallow over a third (34%) of European finance teams’ time.1 With its finance automation technology, Tipalti aims to eradicate this – enabling finance teams to have the time to contribute to strategic work that aids growth.
Building on its success in the UK, the new localised offering and licence enables Tipalti to offer a full spectrum of payment solutions and capabilities to more businesses across Europe. Overcoming inefficiencies, reducing friction in existing payment and administrative finance processes and increasing visibility and control will now be a reality for more businesses in the region, bringing speed and reliability of payments to a currently underserved market.
Tipalti is improving the operations of finance teams across all verticals with automation, including that of German-born Linkvertise. Maximilian Bentein, Head of Publisher at the online marketing service platform said: “Keeping over five-million content creators satisfied and paid on time is no easy task manually. With Tipalti, we have been able to automate the heavy load, keep our customers happy and achieve our ambitious growth plans in the region.
“As a German company with clients across Europe and the world, we’re delighted that this new, truly localised solution is now a reality - giving us an even easier way to handle our payouts and reach our goal in monetising worldwide creativity.”
Just two years after launching in Europe with a UK HQ, and one year after launching in Amsterdam, the unicorn valued at $8.3bn+, currently has over 100 customers in Europe, powered by a growing workforce of over 100 employees.
The launch of a European product and the EMI licence is a key stepping stone for Tipalti’s further European expansion into key European markets, including Germany and the Nordics, with expectations that the continent will bring in at least 20% of the company’s new business by the end of 2024.
Rob Israch, President of Tipalti, said: “We know that economic growth in Europe is predicted to be 1% for 2023 – which lags behind the US which saw 2.4% growth in the second quarter of this year.
“Now more than ever, businesses in the region need localised tools that eradicate manual processes, drive efficiency and give them a competitive edge - because time spent on manual finance processes is time spent away from strategic initiatives that drive growth.
“With our fully localised solution and strategic financial institution partnerships throughout Europe, Tipalti is in a strong position to help businesses achieve the sustainable growth needed. With a huge addressable market to serve, the opportunity for Tipalti in Europe is massive.”
Tipalti also announced that on 21st September, it will host its third annual Illuminate conference in which industry experts come together to discuss how automation, AI and innovation are shaping the future of finance. In addition to this, it will launch its expenses solution to deliver an easy-to-use product that handles employee global reimbursement needs, while connecting seamlessly with its end-to-end AP, mass payments, and procurement solutions. For more information, visit tipalti.com
About Tipalti
Tipalti is the only company handling both Global Partner Payments and Accounts Payable workflows for high-velocity companies across the entire financial operations cycle: onboarding and managing global suppliers, instituting procurement controls, streamlining invoice processing and approvals, managing employee expenses, executing payments around the world and reconciling payables data across a multi-subsidiary finance organisation. Tipalti enables companies to scale quickly by making payables strategic with operational, compliance, and financial controls. Companies can efficiently and securely pay thousands of partners, suppliers, and employees in 196 countries within minutes. Thousands of companies, such as Amazon Twitch, GoDaddy, Roku, WordPress.com, and ZipRecruiter use Tipalti to reduce manual workload by 80% and accelerate the monthly close by 25%, while strengthening financial and spend controls. For more information, visit tipalti.com/en-eu/.
1Tipalti commissioned Insight Avenue to conduct an independent study, comprising 500 interviews with Finance and AP leaders in the US, UK, Netherlands and Belgium. Interviewees were with high-growth businesses (revenue growth of 20% or more in the last 12 months) with 50 – 1,000 employees. Interviews were conducted during March 2023.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230918704176/en/
Contact information
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
Incyte Japan Announces Approval of Zynyz ® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer22.12.2025 08:42:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced the Japan Ministry of Health, Labour and Welfare (MHLW) approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of advanced squamous cell carcinoma of the anal canal (SCAC). "Today's approval marks a significant milestone for patients with advanced anal cancer in Japan – the MHLW’s approval of Zynyz as the first and only first-line treatment for SCAC," said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan G.K. "By offering combination therapy with chemotherapy, Zynyz provides a vital new path forward for patients facing this challenging disease, addressing a significant unmet need in cancer care for patients with SCAC and their families." The approval was based on data from the Phase 3 POD1UM-303/InterAACT2 trial evaluating Zynyz in combination with platinum-based chemotherapy (carboplatin-paclitaxel) in adult patients with metastatic or inoperable
GBC AG Analyst Coverage Report on Mexedia S.p.A. Società Benefit Completed and Published22.12.2025 08:30:00 CET | Press Release
Regulatory News: Mexedia S.p.A. Società Benefit (Euronext Growth Paris: ALMEX, ISIN IT0005450819) (“Mexedia” or the “Company”) informs that the analyst coverage report prepared by GBC AG – one of the leading independent financial research firms in Germany –, developed within an issuer-sponsored research framework, has been completed and is now publicly available. The report follows the re-initiation of analyst coverage by GBC AG previously communicated by the Company and is based exclusively on publicly available information. The content, assumptions and conclusions of the report are solely attributable to the analyst. The GBC AG analyst coverage report is available on the Company’s official website at the following address: https://mexedia.com/en/financial-statements-and-reports/ and on the analyst’s website. Daniel Gilcher, Chief Financial Officer of Mexedia S.p.A. Società Benefit, stated: “The completion and publication of the analyst coverage report by GBC AG represents the conclus
Hisense Joins HEVC Advance Patent Pool22.12.2025 03:06:00 CET | Press Release
Access Advance LLC, the global leader in video codec patent pool licensing, today announced that Hisense Group Holdings Co., Ltd. has joined the HEVC Advance Patent Pool as a Licensee. Hisense joins the recent additions to the Access Advance patent pools, including Xiaomi, MSI, Transsion, and expanded relationships with Huawei, HP and Sharp. Hisense, headquartered in Qingdao, China, is one of the world's largest television manufacturers, with a global presence spanning Asia, Europe, the Americas, and beyond. The company's products reach consumers in more than 160 countries and regions worldwide. "We are pleased to welcome Hisense to the HEVC Advance Patent Pool," said Peter Moller, CEO of Access Advance. "This agreement is the result of extensive engagement between our teams over a considerable period of time. Hisense's decision to join the pool reflects a recognition that transparent, efficient licensing solutions benefit both innovators and implementers across the video technology ec
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom